Fate Therapeutics Inc.
Organization details
- Legal name
- Fate Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FATE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001434316
- EIN
- 65-1311552
- Wikidata ID
- Q30287119
Board of directors
-
Bahram Valamehr · Director · President and CEOSince 2025
-
J. Scott Wolchko · Director · President and CEOSince 2023
-
Jeremy Green · DirectorSince 2023
-
John Mendlein · DirectorSince 2023
-
Karin Jooss · DirectorSince 2023
-
Laura Hamill · DirectorSince 2026
-
Matt Abernethy · DirectorSince 2025
-
Michael Stewart Lee · DirectorSince 2023
-
Neelufar Mozaffarian · DirectorSince 2024
-
Robert Hershberg · DirectorSince 2023
-
Robert S. Epstein · DirectorSince 2023
-
Shefali Agarwal · DirectorSince 2023
- Since 2023
-
William H. Rastetter · DirectorSince 2023
-
Yuan Xu · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.2%
-
97.7%
-
99.7%
Board connections
8 of this board's directors also sit on 19 other boards. 17 are in the same sector.
-
Shattuck Labs Inc. Same sectorvia Jeremy Green and Michael Stewart Lee
-
ADC Therapeutics SA Same sectorvia Timothy Coughlin
-
Absci Corporation Same sectorvia Jeremy Green
-
Adaptive Biotechnologies Corporation Same sectorvia Robert Hershberg
-
AnaptysBio Inc. Same sectorvia Laura Hamill
-
Atara Biotherapeutics Inc. Same sectorvia Jeremy Green
- via Robert Hershberg
-
Dare Bioscience Inc. Same sectorvia William H. Rastetter
-
Iambic Therapeutics Inc. Same sectorvia William H. Rastetter
- via Robert S. Epstein
-
Jazz Pharmaceuticals plc Same sectorvia Laura Hamill
-
Neurocrine Biosciences Inc. Same sectorvia William H. Rastetter
-
Recursion Pharmaceuticals Inc. Same sectorvia Robert Hershberg
-
Scilex Holding Company Same sectorvia Laura Hamill
-
Travere Therapeutics Inc. Same sectorvia Timothy Coughlin
-
Veracyte Inc. Same sectorvia Robert S. Epstein
-
Vir Biotechnology Inc. Same sectorvia Timothy Coughlin
-
Xilio Therapeutics Inc. Same sectorvia Yuan Xu
-
aTyr Pharma Inc. Same sectorvia Timothy Coughlin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $336,388
- 7 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | Adawi Kamal Officer (Chief Financial Officer) | Open-market sale | −6,582 | $2.05 | $13,525 |
| Aug 4, 2026 | Bahram Valamehr Director, Officer (President and CEO) | Open-market sale | −43,947 | $2.46 | $108,110 |
| Aug 4, 2026 | TAHL CINDY Officer (See Remarks) | Open-market sale | −38,800 | $2.46 | $95,448 |
| May 20, 2026 | TAHL CINDY Officer (See Remarks) | Open-market sale | −25,590 | $1.88 | $48,109 |
| May 20, 2026 | Bahram Valamehr Director, Officer (President and CEO) | Open-market sale | −28,946 | $1.88 | $54,418 |
| May 6, 2026 | TAHL CINDY Officer (See Remarks) | Option exercise | +122,220 | $1.32 | $161,330 |
| May 6, 2026 | TAHL CINDY Officer (See Remarks) | Option exercise | +44,444 | $1.05 | $46,666 |
| May 5, 2026 | Robert S. Epstein Director | Option exercise | +25,000 | $1.69 | $42,250 |
| May 5, 2026 | William H. Rastetter Director | Option exercise | +25,000 | $1.69 | $42,250 |
| Apr 20, 2026 | Jeremy Green Director, 10% owner | Other | −8,977,624 | — | — |
| Apr 20, 2026 | Jeremy Green Director, 10% owner | Other | +8,977,624 | — | — |
| Jan 15, 2026 | TAHL CINDY Officer (See Remarks) | Grant or award | +100,000 | — | — |
| Jan 15, 2026 | Adawi Kamal Officer (Chief Financial Officer) | Grant or award | +25,000 | — | — |
| Jan 15, 2026 | Bahram Valamehr Director, Officer (President and CEO) | Grant or award | +335,000 | — | — |
| Jan 9, 2026 | TAHL CINDY Officer (See Remarks) | Open-market sale | −10,589 | $1.06 | $11,224 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Fate Therapeutics Inc.
Who is the CEO of Fate Therapeutics Inc.?
J. Scott Wolchko is Fate Therapeutics Inc.'s President and CEO.
How many directors are on Fate Therapeutics Inc.'s board?
Fate Therapeutics Inc.'s board has 15 directors: Bahram Valamehr, J. Scott Wolchko, Jeremy Green, John Mendlein, Karin Jooss, Laura Hamill, Matt Abernethy, Michael Stewart Lee, Neelufar Mozaffarian, Robert Hershberg and 5 others.
Are Fate Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Fate Therapeutics Inc. insiders made no open-market purchases and sold $336,388 of shares in 7 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="fate-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.